1258545-41-3Relevant academic research and scientific papers
Structure-based design of irreversible human KAT II inhibitors: Discovery of new potency-enhancing interactions
Tuttle, Jamison B.,Anderson, Marie,Bechle, Bruce M.,Campbell, Brian M.,Chang, Cheng,Dounay, Amy B.,Evrard, Edelweiss,Fonseca, Kari R.,Gan, Xinmin,Ghosh, Somraj,Horner, Weldon,James, Larry C.,Kim, Ji-Young,McAllister, Laura A.,Pandit, Jayvardhan,Parikh, Vinod D.,Rago, Brian J.,Salafia, Michelle A.,Strick, Christine A.,Zawadzke, Laura E.,Verhoest, Patrick R.
, p. 37 - 40 (2013/03/14)
A series of aryl hydroxamates recently have been disclosed as irreversible inhibitors of kynurenine amino transferase II (KAT II), an enzyme that may play a role in schizophrenia and other psychiatric and neurological disorders. The utilization of structu
Bicyclic And Tricyclic Compounds As KAT II Inhibitors
-
Page/Page column 48, (2010/12/31)
Compounds of Formula X: wherein A, X, Y, Z, R5, R6a, and R6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
